Allogene Therapeutics Stock (NASDAQ:ALLO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.12

52W Range

$1.99 - $5.78

50D Avg

$2.74

200D Avg

$3.15

Market Cap

$429.83M

Avg Vol (3M)

$2.07M

Beta

0.84

Div Yield

-

ALLO Company Profile


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

232

IPO Date

Oct 11, 2018

Website

ALLO Performance


ALLO Financial Summary


Dec 23Dec 22Dec 21
Revenue$95.00K$243.00K$38.49M
Operating Income$-327.74M$-335.45M$-255.79M
Net Income$-327.26M$-329.81M$-244.84M
EBITDA$-327.74M$-335.45M$-255.79M
Basic EPS-$-2.30$-1.80
Diluted EPS-$-2.30$-1.80

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 07, 24 | 8:59 PM
Q1 24May 13, 24 | 7:31 PM
Q4 23Mar 14, 24 | 8:49 PM

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
VECTVectivBio Holding AG
BPMCBlueprint Medicines Corporation
IPSCCentury Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
EDITEditas Medicine, Inc.
PRMEPrime Medicine, Inc.
VERVVerve Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
GTHXG1 Therapeutics, Inc.
HRTXHeron Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc.
CRBUCaribou Biosciences, Inc.
ANNXAnnexon, Inc.
ITOSiTeos Therapeutics, Inc.
BEAMBeam Therapeutics Inc.
LIFEaTyr Pharma, Inc.